CTLA4 and neoplasm: Moreover, HRRmut (35.99 Muts/Mb) was associated with higher tumor mutation burden (TMB) (P < 0.0001) than HRRwt (5.90 Muts/Mb) (Figure 4B), similar with the patients with anti-CTLA-4 therapy.